No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MEDP240816C420000
- 30.08
- +0.47+1.59%
15min DelayClose Jul 19 16:00 ET
30.08High30.08Low
30.08Open29.61Pre Close1 Volume3 Open Interest420.00Strike Price3.01KTurnover63.00%IV6.83%PremiumAug 16, 2024Expiry Date1.31Intrinsic Value100Multiplier25DDays to Expiry28.77Extrinsic Value100Contract SizeAmericanOptions Type0.5495Delta0.0056Gamma14.28Leverage Ratio-0.5753Theta0.1430Rho7.85Eff Leverage0.4438Vega
Intraday
- 5D
- Daily
News
Notable Earnings After Monday's Close
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know
In the latest market close, Medpace (MEDP) reached $443, with a +1.84% movement compared to the previous day.
Baird Adjusts Medpace Holdings' Price Target to $469 From $456, Keeps Outperform Rating
Medpace Holdings (MEDP) has an average rating of outperform and price targets ranging from $296 to $480, according to analysts polled by Capital IQ.Price: 402.80, Change: +0.40, Percent Change: +0.10
Medpace Holdings Is Maintained at Outperform by Baird
Medpace Holdings Is Maintained at Outperform by Baird
Comments
Investors expect Medpace Holdings to outperform the market, hence its high P/E ratio. Strong future growth anticipation makes investors pay more for the stock, supporting the share price.
The Price Is Right For Medpace Holdings, Inc. (NASDAQ:MEDP) 1
Medpace Holdings' robust conversion of profit to free cash flow is promising. Its underlying earnings potential may even surpass the statutory profit. Its earnings per share have seen a remarkable growth over the past three years.
1
Medpace Holdings' market sentiment remains steady, mirroring EPS growth. The stock's recent performance shows improvement, with a 90% shareholder return over the last year, surpassing the five-year TSR of 41% per year. The strong share price momentum suggests a closer look at the stock may be worthwhile.
Medpace's high P/E is backed by its forecast growth being higher than the wider market. Investors are quite confident in the company's future earnings and seem willing to pay more for the stock, suggesting a bullish outlook.
Insider selling at current price (US$274) is less worrying, but there were no purchases over the past year to boost confidence. A high level of insider ownership often implies interests of all shareholders are considered, though recent history of share sales triggers some hesitation.
Read more